USP9X and plasma cell myeloma: Among the compounds targeting USP9X, a non-specific inhibitor of USP9X, named (EOAI3402143) G9, belonging to the USP9X-second generation inhibitors, has been shown to destabilize the pro-survival protein MCL1 and increased p53 levels, promoting apoptosis in a dose-dependent manner and reducing tumor growth of human myeloma xenograft [125].